Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kyverna Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,727 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 5,093 · Balance 21,727 F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.59 · Expires 2036-05-27 | Direct | 20,582 |
Reported balance
After 2026-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-27 · Grant · Acquired 20,582 · Balance 20,582 F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 20:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 20,582 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001193125-26-248425 · ownership.xml · derivative · entry 2 Aktar Mert · CIK 0002040256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,582 Underlying: Common Stock · 20,582 shares Expires 2036-05-27 F2 · derivative.exercise_date: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 5,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-248425 · ownership.xml · nonDerivative · entry 1 Aktar Mert · CIK 0002040256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,727 F1 · shares: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:32 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 65,351 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000950170-25-080451 · ownership.xml · derivative · entry 2 Aktar Mert · CIK 0002040256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,351 Underlying: Common Stock · 65,351 shares Expires 2035-05-29 F2 · derivative.exercise_date: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 22:32 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 16,634 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080451 · ownership.xml · nonDerivative · entry 1 Aktar Mert · CIK 0002040256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,634 F1 · shares: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| October 21, 2024 Filed Oct 24, 2024 10:05 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 87,741 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0000950170-24-116840 · ownership.xml · derivative · entry 1 Aktar Mert · CIK 0002040256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,741 Underlying: Common Stock · 87,741 shares Expires 2034-10-21 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on each monthly anniversary, such that 100% of the shares subject to the option shall be fully vested and exercisable on the third anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.